2ND INTERNATIONAL WORKSHOP ON
CLINICAL PHARMACOLOGY OF ANTICANCER DRUGS 13 - 14 September 2017 • Madrid, Spain
EVALUATION REPORT
EVALUATION REPORT www.virology-education.com www.expertmedicalevents.com
EXECUTIVE SUMMARY The second International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) was organized on the 13th and 14th September 2017 in Madrid, Spain. It attracted 45 participants from 10 countries, including 11 young investigators from 4 countries. The meeting gathered a cross-disciplinary team of experts and trainees involved in anticancer drug research, in order to present and discuss the latest developments and strategies for the future, in an interactive and sciencefocused setting. The workshop consisted of expert plenary lectures, oral abstract presentations and poser viewing session. In order to ascertain interaction, much time had been allocated to Q&A and discussions; thus providing a unique opportunity to meet colleagues in a scientific focused setting. Special attention was given to the empowerment of young investigators in this region who received a complimentary registration upon acceptance of their abstract.
PROGRAM The program included 12 invited lectures, 10 oral abstract presentations and regular poster viewing sessions. Ample time was allocated for discussion. The evaluation scores of the presentations can be found on pages 14 - 17.
ABSTRACTS The Organizing Committee received 19 abstracts, of which 10 were accepted for oral presentations and 18 for poster presentations. 89% of the respondents reported that the poster session was a valuable element to the program, and 89% indicated that the combination of poster session and welcome drinks was well scheduled.
FUTURE
NEEDS ASSESSMENT A needs assessment was conducted during the event. 94% of the respondents reported that there is a need for a scientific program on clinical pharmacology of anticancer drugs. The respondents indicated that the field would benefit most from the discussions on dose selections strategies (29%), PK-PD modelling (28%), mechanism of interaction (17%), drug development (17%), and novel diagnostic monitoring approaches (9%). 93% of the respondents (strongly) agreed that this year’s program met the mentioned needs/ gaps.
INTENT TO CHANGE
The majority of the respondents very much appreciated the conference to such an extent that they would recommend the meeting to their colleagues (93%) and plan to attend the 2018 meeting (77%). The Organizing Secretariat and the Committee shall revisit and take the comments given by the attendees into account for the preparation of next year’s event. The ICPAD 2018 is scheduled to take place on the 8th and 9th November 2018 in Amsterdam, the Netherlands. In addition, a one day course dedicated to the industry participants will also be organized prior to the main event.
The conference was very well received which is reflected by the evaluation results. 93% of the respondents indicated that the lectures given in this workshop have increased their knowledge of clinical pharmacology of anticancer, 59% agreed that the program was beneficial for the clinical management of their patients, 63% reported that they intended to incorporate the new information into the care of their patients.
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
2
“Excellent groups of experts, good scientific and educational content!”
“Interesting, very open, friendly atmosphere and easy for connecting with colleagues. Sessions very actual and speakers’ performance is really nice.”
TABLE OF CONTENTS Executive Summary............................................................................... 2 Meeting Description............................................................................... 5 Committees............................................................................................ 6 Registrant Demographics...................................................................... 8 Meeting Metrics................................................................................... 10 Attendee Demographics...................................................................... 11 Results of Needs Assessment............................................................. 12 Results of Meeting Evaluation............................................................. 13 Invited lectures, abstract-driven presentations ...................................14 Poster viewing and social programs ....................................................18 Intent to change.....................................................................................18 Meeting objectives.................................................................................19 Conference organization........................................................................19 General conference experience.............................................................19 Participants’ remarks............................................................................20
Conclusion........................................................................................... 21 Acknowledgements............................................................................. 22
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
4
MEETING DESCRIPTION BACKGROUND
UNIQUE MEETING FEATURES
Understanding the pharmacology of anticancer drugs is pivotal to designing optimal treatment. Drug exposure is significantly influenced by drug interactions, transporter mediated interactions, and patients’ physiologic and genetic characteristics. These factors are central for therapeutic efficacy, failure or toxicity. Despite great progress, many pharmacologic opportunities to improve both efficacy and quality of life still exist. The meeting gathered a cross-disciplinary team of experts and trainees involved in anticancer drug research, in order to present and discuss the latest developments and strategies for the future, in an interactive and sciencefocused setting. The workshop consisted of expert plenary lectures and abstract-driven presentations. In order to ascertain interaction, much time was allocated to Q&A and discussions.
MEETING OBJECTIVES
This workshop provided a unique international translational platform for interchange between clinical pharmacologists, (hospital) pharmacists, industry researchers and government representatives. •
This workshop is intended as a compact, focused meeting to encourage crossdisciplinary scientific dialogue and in-depth discussions among all attendees, including presenters.
•
This meeting is a stepping stone for young medical professionals to present their research in an informal and encouraging setting. We encourage their participation by offering them a complimentary registration (for more information see meeting website).
•
Participants have a great opportunity to meet with their international colleagues and expand their network.
TARGET AUDIENCE
The meeting aims at: • To gather professionals in the field of pharmacology of anticancer drugs in an interactive workshop setting; • To provide a platform for presentation and discussion of the latest pharmacological developments in the field;
The target audience of this meeting consisted of medical oncologists, internal medicine doctors, clinical pharmacologists, hospital pharmacists, industry researchers, government representatives and other experts involved in this field of research.
• To map current studies and latest results; • To translate new data into treatment opportunities; • To educate clinicians on pharmacological challenges that need to be addressed with the implementation of current and new drugs.
FORMAT This 1.5 days regional meeting consisted of invited lectures, oral abstract- and poster presentations. In order to ascertain an interactive workshop setting, much time was allocated to discussion. As the meeting was abstract driven, it was an excellent platform for young investigators to present their research. To ensure the quality of the accepted abstracts, all submitted abstracts went through a blind, peer-reviewed process conducted by the members of the Organizing and Scientific Committees.
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
5
COMMITTEES ORGANIZING COMMITTEE
Etienne Chatelut,
George Demetri
Nielka van Erp
Lena Friberg
PharmD, PhD University Institute Cancer Toulouse Oncopole, France
MD Harvard Medical School, USA
PharmD, PhD Radboud University Medical Center, the Netherlands
PharmD, PhD Uppsala University, Sweden
Maria-Jesus Garrido
Howard Gurney
Michelle Rudek
PhD University of Navarra, Spain
MBBS, FRACP Macquarie University, Westmead Hospital, Australia
PharmD, PhD Johns Hopkins University, USA
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 3-14 September 2017, Madrid, Spain
6
COMMITTEES SCIENTIFIC COMMITTEE Stephen Ackland, MBBS, FRACP, GAICD Calvary Mater Newcastle Hospital, Australia
Federico Innocenti, MD, PhD The University of North Carolina at Chapel Hill, USA
Stijn Koolen, PharmD, PhD Erasmus Medical Center, the Netherlands
Jan Schellens, MD Netherlands Cancer Institute, the Netherlands
INDUSTRY LIAISON COMMITTEE Dinesh de Alwis, PhD Merck Research Labs, USA
Barbara Brennan Roche, USA
René Bruno, PhD Genentech, France
Owen Jones, PhD Astra Zeneca, United Kingdom Bart Ploeger Bayer, Germany
Elisabeth Rouits, PharmD, PhD Debiopharm, Switzerland
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 3-14 September 2017, Madrid, Spain
7
REGISTRANT DEMOGRAPHICS This section outlines key statistical information of the meeting registrants. Registrants were the persons who had preregistered for the workshop, but not necessarily attended the workshop in the end.
NUMBER OF REGISTRATIONS 45 registrations from 10 countries.
NUMBER OF YOUNG INVESTIGATORS 11 young investigators joined the workshop this year. The Netherlands
4
Germany
3
France
3 Australia 1
GEOGRAPHICAL DISTRIBUTION OF REGISTRANTS Most of the attendees came from the Netherlands (18%) followed by France (16%), United States (16%), Spain (13%) and Germany (11%). Netherlands 8
Spain 6
United Kingdom
France 7
Germany 5
Sweden 2
United States
Australia 4
Switzerland 2
7
3
Italy 1
PROFESSIONAL BACKGROUND OF REGISTRANTS 29% of the registrants work mainly as a pharmacist (PharmD), 16% are researchers (PhD), and 16% are pharmacologists. 37% of the registrants indicated that they work in the area of pharmacology and 27% work in oncology. Occupation
Type of organization
N= 45 (answers) out of 45 registrants
N=45 (answers) out of 45 registrants
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
8
REGISTRANT DEMOGRAPHICS Area of expertise Multiple answers were allowed. N=70 (answers) out of 45 registrants
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
9
MEETING METRICS How did you become aware of this conference: Multiple answers were allowed. N=33 (answers) out of 31 feedback forms
I was motivated to attend this meeting because of: Multiple answers were allowed. N=74 (answers) out of 31 feedback forms
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
10
ATTENDEE DEMOGRAPHICS This section shows the number of the participants who actually attended the event. During the meeting, they were asked to fill out a needs assessment survey, and evaluate each presentation, logistical arrangements, and overall event experience. Their responses and feedback can be found on the next pages.
NUMBER OF PARTICIPANTS 45 participants attended the ICPAD 2017.
PERCENTAGE OF RETURNING AND NEW PARTICIPANTAS N=58 (answers) out of 60 feedback forms
NUMBER OF PARTICIPANTS PER SESSION 13 September AM PM
expert medical events
14 September
Session 1: 44
Session 5: 38
Session 2: 42
Session 6: 37
Session 3: 42 Session 4: 41
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
11
RESULTS OF NEEDS ASSESSMENT A needs assessment was conducted on Day 1 of the event. 94% of the respondents reported that there is a need for a scientific program on clinical pharmacology of anticancer drugs. The respondents indicated that the field would benefit most from the discussions on dose selections strategies (29%), PK-PD modelling (28%), mechanism of interaction (17%), drug development (17%), and novel diagnostic monitoring approaches (9%). 93% of the respondents (strongly) agreed that this year’s program met the mentioned needs/ gaps.
BACKGROUND OF RESPONDENTS Thirty-four percent of the respondents work mainly as pharmacists, followed by pharmacologists (21%), and researchers (18%).
Occupation
There is a need for a scientific program on clinical pharmacology of anticancer drugs
N=44 (answers) out of 31 assessment forms Multiple answers were allowed.
N=31(answers) out of 31 assessment forms
Discussions on, which scientific gaps do you feel the field would benefit most from
This year’s program has met the above-mentioned needs/gaps you selected
N=87 (answers) out of 31 assessment forms Multiple answers were allowed.
N=29 (answers) out of 31 assessment forms
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
12
RESULTS OF MEETING EVALUATION NUMBER OF RESPONDENTS PER DAY 13 September
14 September
N=31
N=29
BACKGROUND OF RESPONDENTS Thirty-six percent of the respondents are from pharmaceutical companies, followed by university (32%), and hospital (32%). 37% of them are pharmacists, pharmacologists (30%), and researchers (14%). Over 50% work in the field of pharmacology, followed by oncology (41%). Type of organization
Occupation
Multiple answers were allowed. N=66 (answers) out of 60 feedback forms
Multiple answers were allowed. N=84 (answers) out of 60 feedback forms
Area of expertise Multiple answers were allowed. N=73 (answers) out of 60 feedback forms
Others: • Applied Mathematics (N=2) • Regulator (N=1) • Not specified (N=1)
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
13
RESULTS OF MEETING EVALUATION INVITED LECTURES, ABSTRACT-DRIVEN PRESENTATIONS WEDNESDAY 13 SEPTEMBER Session 1: PK of Monoclonal Antibodies ADA-formation and its effect on Mab PK Maria-Jesus Garrido, Spain
PK and PKPD considerations for dose selection in the development of pembrolizumab Dinesh de Alwis, USA
N=31 (Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
90%
10%
0%
1
Content is relevant to my work
67%
23%
10%
1
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
100%
0%
0%
0
Content is relevant to my work
83%
14%
3%
0
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
84%
16%
0%
0
Content is relevant to my work
71%
26%
3%
0
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
93%
7%
0%
1
Content is relevant to my work
80%
13%
7%
1
Session 2: TDM for Targeted Therapies Model-based TDM for oncology drugs Ron Keizer, USA
Physiologically based PK model vs. Population PK approach during drug development Italo Poggesi, Italy
N=31
Session 3: Drug-Drug Interaction
N=31
Oncology DDI Website Nielka van Erp, the Netherlands
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
90%
7%
3%
0
Content is relevant to my work
74%
13%
13%
0
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
81%
19%
0%
0
Content is relevant to my work
68%
22%
10%
0
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
86%
10%
4%
0
Content is relevant to my work
69%
24%
7%
0
Clinical case discussions Howard Gurney, Australia
Clinical case discussions Guillemette Benoist, the Netherlands
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
14
RESULTS OF MEETING EVALUATION Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanoma. (Abstract # O_01) Marine Rousset, France Evaluation of a physiological based pharmacokinetic model to evaluate the influence of covariates on sunitinib exposure (Abstract # O_02) Ashley Hopkins, Australia
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
90%
7%
3%
0
Content is relevant to my work
68%
26%
6%
0
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
94%
6%
0%
0
Content is relevant to my work
72%
19%
9%
0
Session 4: Drug Transporters and Epigenetic Drug transporters as modulators of chemotherapy toxicity Alex Sparreboom, USA
DNA-methylation of ADME genes Matthias Schwab, Germany
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer (Abstract # O_03) Litaty Mbatchi, France Quantification of antidrug-antibodies impact on drug exposure of a new anti-cancer drug using a population PK (Abstract # O_04) Candice Jamois, Switzerland
expert medical events
N=31 (Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
100%
0%
0%
3%
Content is relevant to my work
77%
17%
6%
0%
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
94%
3%
3%
1
Content is relevant to my work
67%
20%
13%
0
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
89%
7%
4%
2
Content is relevant to my work
69%
21%
10%
1
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
89%
11%
0%
0
Content is relevant to my work
70%
15%
15%
0
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
15
RESULTS OF MEETING EVALUATION THURSDAY 14 SEPTEMBER Session 5: Optimal Study Design
N=29
Optimal design – potential application in oncology drug development and clinical practice Andrew Hooker, Sweden Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens (Abstract # O_05) Aureila De Vries Schultink, the Netherlands The use of mathematical modelling to predict efficacious doses and schedules from pre-clinical data for the ATM inhibitor AZD0156 in combination with irinotecan (Abstract # O_06) Michael Davies, UK
(Strongly) Agree
Neither agree nor disagree
(Strongly) Disagree
N/A
Topic is interesting
100%
0%
0%
0
Content is relevant to my work
90%
7%
3%
0
Strongly (Agree)
Neither agree nor disagree
Strongly (Disagree)
N/A
Topic is interesting
86%
11%
3%
0
Content is relevant to my work
75%
21%
4%
0
Strongly (Agree)
Neither agree nor disagree
Strongly (Disagree)
N/A
Topic is interesting
93%
7%
0%
0
Content is relevant to my work
68%
21%
11%
0
Session 6: Cancer Drug Regulation
N=29
Treatment optimisation in cancer drug regulation, adults / paediatrics Lucas Moreno, Spain
Drug-exposure response models for safety and efficacy in the use of doxorubicin plus lurbinectedin (Abstract # O_07) Carlos Fernandez, Spain Assessment of the release of daunorubicin from liposomes after administration of daunoXome® using population pharmacokinetics (Abstract # O_08) Martina Liebich, Germany
expert medical events
Strongly (Agree)
Neither agree nor disagree
Strongly (Disagree)
N/A
Topic is interesting
96%
4%
0%
0
Content is relevant to my work
81%
15%
4%
0
Strongly (Agree)
Neither agree nor disagree
Strongly (Disagree)
N/A
Topic is interesting
89%
8%
3%
0
Content is relevant to my work
74%
15%
11%
0
Strongly (Agree)
Neither agree nor disagree
Strongly (Disagree)
N/A
Topic is interesting
85%
15%
0%
0
Content is relevant to my work
56%
24%
20%
1
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
16
RESULTS OF MEETING EVALUATION The impact of dose and simultaneous use of acid reducing agents on the effectiveness of vemurafenib in metastatic BRAF V600 mutated melanoma: a retrospective cohort study (Abstract # O_09) Nielka van Erp, the Netherlands Development of an online drug-drug interaction resource to support prescribing of oncolytics (Abstract # O_10) Nienke Lankheet, the Netherlands
expert medical events
Strongly (Agree)
Neither agree nor disagree
Strongly (Disagree)
N/A
Topic is interesting
92%
8%
0%
2
Content is relevant to my work
80%
16%
4%
1
Strongly (Agree)
Neither agree nor disagree
Strongly (Disagree)
N/A
Topic is interesting
91%
9%
0%
2
Content is relevant to my work
79%
13%
8%
1
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
17
RESULTS OF MEETING EVALUATION POSTER VIEWING AND SOCIAL PROGRAMS (Strongly) Agree
Neither agree
(Strongly) Disagree
N/A
nor disagree
N=27 The poster session was a valuable element to the program
89%
11%
0%
1
The combination of the poster session and welcome drinks was well scheduled
89%
7%
4%
1
The workshop dinner (Networking Dinner) was well organized
100%
0%
0%
0
(Strongly) Agree
Neither agree
(Strongly) Disagree
N/A
INTENT TO CHANGE nor disagree
N=27 The lectures given in this workshop have increased my knowledge of clinical pharmacology of anticancer drugs
93%
4%
3%
0
This program is beneficial for the clinical management of my patients
58%
42%
0%
14
I intend to incorporate the new information into the care of my patients
64%
27%
9%
14 %
I will be able to implement the gained knowledge without any problems
14%
Some of the following factors might prevent me from implementing the gained knowledge: % My current office and practice systems might not accommodate the changes
29%
My patients/ client might have trouble complying with these changes/ strategies
14%
These changes might be too time consuming
14%
The medications/ procedures discussed might not be available for my patients/ clients
5%
Other reason(s), please specify
24%
Other reasons: •
I don’t treat patients.
•
Many clinicians in my hospital aren’t of PK, they don’t trust pharmacology, thus it is difficult to convince them to perform TDM.
•
Impact is more on research.
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
18
RESULTS OF MEETING EVALUATION MEETING OBJECTIVES (Strongly) Agree
Neither
(Strongly) Disagree
N/A
agree nor
N=26
disagree
To gather professionals in the field of pharmacology of anticancer drugs in an interactive workshop setting
92%
8%
0%
0
To provide a platform for presentation and discussion of the latest pharmacological developments in the field
88%
8%
4%
0
To map current studies and lastest results
62%
23%
15%
0
To translate new data into treatment opportunities
76%
12%
12%
1
To educate clinicians on pharmacological challenges that need to be addressed with the implementation of current and new drugs
84%
4%
12%
0
(Very) Good
Average
(Very) Poor
N/A
Content of electronic announcements (newsletters)
88%
8%
4%
2
Frequency of electronic announcements (newsletters)
87%
13%
0%
3
Information on the conference website
85%
11%
4%
1
Online registration process
75%
13%
12%
4
Online abstract submission process
78%
11%
11%
11
Meeting venue
89%
11%
0%
0
Meeting room
82%
11%
7%
0
Audiovisuals
93%
7%
0%
0
Food & Beverage
100%
0%
0%
0
Onsite logistics
97%
3%
0%
0
Service level of Conference Secretariat
96%
4%
0%
1
CONFERENCE ORGANIZATION N=28
GENERAL CONFERENCE EXPERIENCE N=28
(Very) Good
Average
(Very) Poor
N/A
Overall event experience
100%
0%
0%
0
Opportunity of networking
100%
0%
0%
0
Content of the educational activity
100%
0%
0%
1
Time allocation for discussion
93%
7%
0%
0
Time allocation per presentation
96%
4%
0%
0
Neither
(Strongly) Disagree
N/A
(Strongly) Agree
agree nor disagree
No commercial bias (product selling) perceived
96%
4%
0%
1
I would recommend this educational event to my peers
93%
7%
0%
0
I plan to attend this event next time
77%
23%
0%
1
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
19
RESULTS OF MEETING EVALUATION PARTICIPANTS’ REMARKS •
Excellent groups of experts, good scientific and educational content!
•
Inspiring!
•
Interesting, useful for networking, good panel of speakers.
•
A nice choice of current (hot) topics and methods in the area of oncology bridging novel research and clinical practice. Great opportunity to network, and get in contact with colleagues with similar interests, from all over the world.
•
Interesting, very open, friendly atmosphere and easy for speaking with everybody. Sessions very actual and speakers’ performance is really nice.
•
Great organization.
•
Great!
PROGRAM SUGGESTION •
Program specialised/ worker representative to special area and modelling, network development, etc.
•
More PBPK& PKPD modelling.
•
Modelling in the area/ connecting pharmacoeconomic aspects, invite speakers from EMAI for ?
•
Combined principal and translational topics would be interesting.
•
More place for pharmacological / clinical case in order to better share ideas and day-to-day practice either from academic/industry constraints.
•
Include a choice of recline phard characteristics of latest confounds.
•
Dare to go for at least 2 full days.
•
Interested and development focus (now somewhat too academic focus) from drug industry & regulations.
•
Less abstract driven presentation and more invited speakers. More session about new trial design.
•
Strong communications/ focusing on original.
•
Program of Day 1 was too long, please till around 16.30 hour.
•
The poster that were also presented in oral presentation: this is a little bit double work. I really learned a lot form the invited speakers!
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
20
CONCLUSION The Organizing Secretariat and the Organizing Committee are pleased with the results of the second International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD). Most of the participants were impressed by the quality of the scientific content and the time allocation for the discussions. The majority also reported that they were satisfied with the overall meeting logistical arrangements and agreed it was a well-organized event. Both the evaluation results and the participants’ remarks proved the success and the importance of this conference. The Organizing Secretariat and the Organizing Committee will further discuss the preparation and the development of the scientific program for the 3rd edition in 2018, scheduled to take place on the 8th and 9th November 2018 in Amsterdam, the Netherlands. In addition, a one day course dedicated to the industry participants will also be organized prior to the main event.
“Inspiring!” “Great opportunity to network, and get in contact with colleagues with similar interests, from all over the world.”
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
21
ACKNOWLEDGEMENTS SUPPORTER LEVEL SPONSORS
PARTNERS
MEDIA PARTNER
expert medical events
Evaluation Report - 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs 13-14 September 2017, Madrid, Spain
22
www.expertmedicalevents.com